(E)-Cefodizime ((E)-THR-221) is an antibiotic. (E)-Cefodizime can selectively bind to penicillin-binding proteins (PBPs) and inhibit the synthesis of the bacterial cell wall, thereby exerting antibacterial activity. (E)-Cefodizime is promising for research of various bacterial infectious diseases, such as for preoperative infection prophylaxis.

(E)-2-Hexadecenal (trans-2-Hexadecenal) is an MLK3 activator that induces cytoskeletal remodeling, leading to cell rounding, detachment, and ultimately apoptosis in human and mouse cells. (E)-2-Hexadecenal activates the MLK3 signaling pathway, phosphorylating MKK4/7 and JNK, subsequently activating downstream targets of JNK, such as c-Jun phosphorylation, cytochrome c release, Bax activation, Bid cleavage, and Bim translocation to mitochondria. (E)-2-Hexadecenal has potential applications in research related to sphingolipid signaling pathways.

(6E)-SR 11302 is a E-isomer of SR 11302. SR 11302 is an activator protein-1 (AP-1) transcription factor inhibitor. SR 11302 is a retinoid that specifically inhibits AP-1 activity without activating the transcription of retinoic acid response element (RARE).

(4-Phenylphenoxy) phosphonic acid is a protein tyrosine phosphatase (PTP) inhibitor (KM: 86 μM). (4-Phenylphenoxy) phosphonic acid can be used in tuberculosis research.

(3S,5S)-Fluvastatin sodium is the isomer of Fluvastatin sodium. Fluvastatin sodium is a first fully synthetic, competitive HMG-CoA reductase inhibitor.

(3aS,4R,9bR)-G-1 is a highly selective G protein-coupled receptor GPR30 (GPER) agonist with a Ki value of approximately 7 nM. (3aS,4R,9bR)-G-1 activates rapid signaling pathways such as intracellular calcium mobilization and PI3K signaling through GPR30, promoting uterine epithelial cell proliferation and exerting antidepressant effects. (3aS,4R,9bR)-G-1 is promising for research of breast cancer and depression.

(2S,4R)-Teneligliptin is a selective inhibitor of dipeptidyl peptidase IV (DPP-4). (2S,4R)-Teneligliptin increases the plasma concentration of active glucagon-like peptide-1 (GLP-1), which promotes insulin secretion in response to elevated blood glucose levels, exerting hypoglycemic activity. (2S,4R)-Teneligliptin is promising for research of type 2 diabetes.

(2R)-RXP470.1 ((2R)-RXP-470) is the (2R)-isomer of RXP470.1 on a cross-clade panel of 208-HIV-1 strains. BMS-818251 interacts with gp120 residues from the conserved β20-β21 hairpin to improve potency.

(1S,2R,7S)-Sitafloxacin (DU-6856) is an enantiomer of Sitafloxacin. (1S,2R,7S)-Sitafloxacin is a topoisomerase inhibitor. (1S,2R,7S)-Sitafloxacin is an antibiotic. (1S,2R,7S)-Sitafloxacin has inhibitory activity against Escherichia coli DNA gyrase (IC50 0.18 μg/mL) and Staphylococcus aureus topoisomerase IV. (1S,2R,7S)-Sitafloxacin has antibacterial activity and can be used in the study of various bacterial infections.

(1R,5Z)-Calcitriol ((1R,5Z)-1,25-Dihydroxyvitamin D3) is a Calcitriol isomer. Calcitriol is the most active metabolite of vitamin D and also a vitamin D receptor (VDR) agonist.

(±)-Pellotine hydrochloride (Compound 2) is an alkaloid, which is found in L. diffusa and L. fricii. (±)-Pellotine hydrochloride decreases locomotor activity and the amount of rapid eye movement (REM) sleep in mice.

(Rac)-1-Oleoyl lysophosphatidic acid is an isomer of 1-Oleoyl lysophosphatidic acid sodium.

III-31-C is a (hydroxyethyl)urea γ-secretase inhibitor. III-31-C inhibits Aऔ production with an IC50 of 10 nM in the cell-free γ-secretase assay and 200 nM in APP-transfected cells. III-31-C can be used in Alzheimer's disease research.

(9R)-RO7185876 (Compound example 16) is a γ-secretase inhibitor. (9R)-RO7185876 inhibits Αβ42 secretion. (9R)-RO7185876 can be used for the researches of Alzheimer's disease, cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, multi-infarct dementia, dementia pugilistica or Down syndrome.

NCB-0970 is the negative control of NCB-0846. (R)-Norfluoxetine is a potent serotonin re-uptake inhibitor, with a Ki of 13 nM. (R)-Norfluoxetine can be used for the research of depression.

EXQ-2d is the inhibitor for tankyrase and inhibits TNKS1 and TNKS2 with an IC50 of 48.8 nM and 13.8 nM (pIC50=7.31 and 7.86). EXQ-2d inhibits WNT/β-catenin signaling pathway with IC50 of 515 nM. EXQ-2d exhibits anti-proliferative activity in cancer cells COLO 320DM and RKO with GI50 of 4.9 μM and 77 μM.

BMD4503-1 is a quinoxaline derivative. BMD4503-1 can inhibit the LRP5/6-Sclerostin interaction and regulate the Wnt signaling pathway.

21H7 is a selective inhibitor of the Wnt/b-catenin pathway. 21H7 markedly inhibits the growth of HFs. 21H7 potently decreases growth of breast and colon cancer cells.

1(R),2(S)-epoxy Cannabidiol (Compound 2a) is a structural analogue of phytocannabinoidsphytocannabinoids. 1(R),2(S)-epoxy Cannabidiol exhibits potent inhibitory activity against Wnt/β-catenin pathway. 1(R),2(S)-epoxy Cannabidiol is promising for research of neuroprotective agents.

GSK-3β probe-1 (10c) is a GSK-3β probe (Ex = 341 nm, Em= 574nm, ɛ= 3.51 × 104L/mol·cm−1) and can be be used in the study of Alzheimer's disease.

2-Cyanoethylalsterpaullone (compound 7) is an Alsterpaullone derivative and a PI3K/Akt signalling activator which promotes epithelium repair. Hydroxy celecoxib can be utilized in asthma research.

WAY-606344 (Compound 97) is a Casein kinase 1δ inhibitor. WAY-606344 is promising for research of Alzheimer's disease.

CK1δ/CK1ε liagnd-1 is the ligand for CK1δ/CK1ε that can be used for synthesis of CK1 PROTAC degrader AH078.

AH078 (compound 37) is a PROTAC degrader that selectively targets CK1δ and CK1ε, and has low targeting for CK1α.

(R,R)-BMS-986397 is a CK1α degrader (DC50 between 0.1-0.5 pM). (R,R)-BMS-986397 can be used in anti-leukemia research.

Lenvatinib N-Oxide (Lenvatinib impurity 10) is the impurity of Lenvatinib. DCG04 is a multivalent ligand for the mannose-6-phosphate receptor. DCG-04 is an activity-based probe for cysteine cathepsins, and can be used for labelling numerous cysteine cathepsins in cell and tissue lysates.

(Z)-SU14813 is an analog of SU14813. CAY10568 is physically smaller and less hydrophobic than the QX-314. CAY10568 can be used in studies of inflammation and pain perception.

VMD-928 is an orally active, allosteric, irreversible and selective tropomyosin receptor kinase A (TrkA) inhibitor. VMD-928 blocks the downstream signaling pathways triggered by the binding of nerve growth factor (NGF) to TrkA, thereby inhibiting cell proliferation, invasion, and promoting cancer cell death. VMD-928 is promising for research of various cancers, including prostate cancer, thymic carcinoma, mesothelioma, squamous cell carcinoma of the head and neck, squamous cell carcinoma of the lung, ovarian cancer, hepatocellular carcinoma.

BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable.

TG-100435 is a multitargeted, orally active protein tyrosine kinase inhibitor, with Ki of 13 to 64 nM for Src, Lyn, Abl, Yes, Lck, and EphB4. TG-100435 plays an important role in cancer research.